Skip to main content

Our mission

We create inspired medicines that matter to cancer patients based on our expertise and ADC technologies

Our ADC technology platforms

In our technology platforms, we use a variety of different payloads to research, manufacture and clinically develop highly effective ADCs for the treatment of a variety of malignant hematological and solid tumors. ADCs combine the high affinity and specificity of antibodies with the potency of small toxic molecules to fight cancer.

With our unique expertise in the active ingredient Amanitin from the green death cap mushroom, we have developed a patented and proprietary ATAC technology. The toxin's unique mode of action offers the opportunity to break through drug resistance and eliminate even quiescent tumor cells, which could lead to significant advances in cancer therapy – even for patients who no longer respond to any other treatment.

News

PR: Heidelberg Pharma: Promising New Clinical Data on Lead ADC-Candidate HDP-101 to be Presented at ASH Annual Meeting 2024
06 November 2024
Open
PR: Heidelberg Pharma to Participate in Leading Scientific and Financial Conferences in November 2024
24 October 2024
Open
PR: Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2024
10 October 2024
Open
PR: Heidelberg Pharma: New Clinical Data on Lead ADC Candidate HDP-101 Presented at IMS 2024 Demonstrating Complete Remission in One Patient
01 October 2024
Open

Meet us

Präsentation

ASH Annual Meeting and Exposition

7. - 10. Dezember

    Partner Information

    TitleDate
    Telix: First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients
    28 November 2024
    Read more
    Telix: First Patient Dosed in Phase II ‘CA-NINE’ Trial of TLX250-CDx for Detection of Recurrent Kidney Cancer After Surgery
    3 October 2024
    Read more
    Telix: 'Highly Accurate': Telix's Phase III ZIRCON Trial for Kidney Cancer Imaging Published in The Lancet Oncology
    11 September 2024
    Read more
    Telix: Telix Completes TLX250-CDx (Zircaix®) BLA Submission for Kidney Cancer Imaging
    3 June 2024
    Read more